Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non –muscle‐invasive bladder cancer (NMIBC): A cohort analysis
In conclusion, despite moderate accuracy, EORTC provided the best recurrence and progression prediction for a mixed population of patients treated with, or without BCG, and without immediate postoperative chemotherapy.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Mateusz Jobczyk,
Konrad Stawiski,
Wojciech Fendler,
Waldemar R óżański Tags: ORIGINAL RESEARCH Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Study | Urology & Nephrology